Prurigo Nodularis Learning Hub

Welcome to the PN learning hub focused on key scientific education on bullous pemphigoid, featuring ADVENT resources.

Prurigo nodularis (PN) is a chronic skin disease characterized by highly pruritic nodules and associated with a high burden of disease. View the resources below to learn about a variety of topics related to PN.
 

Pathophysiology of PN

Explore the pathophysiology of PN including the role of type 2 inflammation.

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis
Type 2 Inflammation
expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

Clinical Presentation, Diagnosis and Burden of PN

Understand the clinical presentation, diagnostic process and burden of PN.

ADVENT On Air | Exploring PN as a Distinct and Unique Disease
Dermatology
Podcast

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

Prurigo Nodularis Events of Interest

Prurigo Nodularis Events of Interest highlight congresses and latest educational opportunities relating to understanding the science of Prurigo Nodularis.

EADV 2025
Congress

EADV 2025 Congress

ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.

Related events

Congress

EADV 2025 Congress

Congress

ADVENT at EADV 2024

Congress

ADVENT in Orlando, 2025

Test your knowledge

Check your understanding of the latest clinical insights and disease management.
Dermatology
MD, MA

Katrina Abuabara

Dermatology
ANP-BC, DCNP, FAANP, MSN

Lakshi Aldredge

Dermatology
MD, PhD

Paolo Amerio

Dermatology
MD, MPH

April Armstrong

Dermatology
MD

Matthias Augustin

Dermatology
MD

Christine Bangert

Dermatology
MD, PhD

Eulàlia Baselga

Dermatology
MD

Lisa Beck

Dermatology
MD

Anna Belloni Fortina

Dermatology
MD, PhD, MDRA

Thomas Bieber

Allergy/Immunology
MD

Tilo Biedermann

Dermatology
MD

Robert Bissonnette

MAT-GLB-2504170 - 1.0 - 10/2025

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United Arab EmiratesChange country/region